Dov Elefant - 19 Mar 2026 Form 4 Insider Report for FEMASYS INC (FEMY)

Reporting relationship: Chief Financial Officer
Issuer ticker: FEMY
Reported as of: 19 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 27 Mar 2026, 17:00:26 UTC
Prior SEC filing: 20 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Kathy Lee-Sepsick, Attorney-in-fact

Key filing fact

Dov Elefant filed Form 4 for FEMASYS INC (FEMY) on 27 Mar 2026.

Key facts

This page summarizes Dov Elefant's Form 4 filing for FEMASYS INC (FEMY).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 27 Mar 2026, 17:00.

Change

Previous filing in this sequence was filed on 20 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001326487 Primary reporting owner

Elefant Dov

Relationship: Chief Financial Officer
Address: C/O FEMASYS INC., 3950 JOHNS CREEK COURT, SUITE 100, SUWANEE
Signature: /s/ Kathy Lee-Sepsick, Attorney-in-fact
Signature date: 27 Mar 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

FEMY transaction Derivative

Series D-1 Warrants

Award

Transaction value
Shares: +34,122
Change %
Price
Shares after: 34,122
Date: 19 Mar 2026
Ownership: Direct
Underlying class: Common stock, par value $0.001 per share
Underlying amount: 34,122
Exercise price: $0.5800
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Holder may, at its option, exercise the Series D-1 Warrants, subject to the terms and conditions thereof, at an initial exercise price of $0.58 per share of Common Stock. The exercise price is subject to adjustment in accordance with the terms of the Series D-1 Warrants and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions.

Footnote F2

The Holder's ability to exercise the subject Warrant for shares of Common Stock is subject to certain limitations, in accordance with rules of the Nasdaq Capital Market.

Footnote F3

The reported securities were issued to the reporting person in a private placement as consideration in connection with that certain Omnibus Amendment and Consent Agreement, dated as of March 19, 2026 by and among the Company, the reporting person and the other parties thereto.